Patients at high risk for sudden cardiac death (SCD) may benefit from wearable cardioverter defibrillators (WCD) by avoiding immediate implantable cardioverter defibrillator (ICD) implantation. Different factors play an important role including patient selection, compliance and optimal drug treatment. We aimed to present real world data from 4 centers from Germany and Switzerland. Between 04/2012 and 03/2019, 708 patients were included in this registry. Patients were followed up over a mean time of 28 \(\pm\) 35.5 months. Outcome data including gender differences and different etiologies of cardiomyopathy were analyzed. Out of 708 patients (81.8% males, mean age 61.0 \(\pm\) 14.6), 44.6% of patients had non-ischemic cardiomyopathy, 39.8% is...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the use of d...
ObjectivesThe aim of this study was to describe usage of the wearable cardioverter-defibrillator (WC...
The study was designed to assess patient adherence to wearable cardioverter defibrillator as an indi...
Patients at high risk for sudden cardiac death (SCD) may benefit from wearable cardioverter defibril...
International audienceAbstract Aims We aimed to provide contemporary real-world data on wearable car...
International audienceAims : We aimed to provide contemporary real-world data on wearable cardiovert...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the ...
INTRODUCTION The wearable cardioverter-defibrillator (WCD) has established itself in treatment of...
Abstract Background Heart failure (HF) patients have a high risk of death, and implantable cardiover...
Abstract Background The wearable cardioverter-defibrillator (WCD) has emerged as a valuable tool to ...
Background. Wearable cardioverter-defibrillators (WCD, LifeVest, ZOLL) can protect from sudden cardi...
Sudden cardiac death (SCD) is the most frequent cause of cardiovascular death in industrialized nati...
ObjectivesThe purpose of this study was to determine patient compliance and effectiveness of antiarr...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the use of d...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the use of d...
ObjectivesThe aim of this study was to describe usage of the wearable cardioverter-defibrillator (WC...
The study was designed to assess patient adherence to wearable cardioverter defibrillator as an indi...
Patients at high risk for sudden cardiac death (SCD) may benefit from wearable cardioverter defibril...
International audienceAbstract Aims We aimed to provide contemporary real-world data on wearable car...
International audienceAims : We aimed to provide contemporary real-world data on wearable cardiovert...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the ...
INTRODUCTION The wearable cardioverter-defibrillator (WCD) has established itself in treatment of...
Abstract Background Heart failure (HF) patients have a high risk of death, and implantable cardiover...
Abstract Background The wearable cardioverter-defibrillator (WCD) has emerged as a valuable tool to ...
Background. Wearable cardioverter-defibrillators (WCD, LifeVest, ZOLL) can protect from sudden cardi...
Sudden cardiac death (SCD) is the most frequent cause of cardiovascular death in industrialized nati...
ObjectivesThe purpose of this study was to determine patient compliance and effectiveness of antiarr...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the use of d...
INTRODUCTION Sudden cardiac death caused by malignant arrhythmia can be prevented by the use of d...
ObjectivesThe aim of this study was to describe usage of the wearable cardioverter-defibrillator (WC...
The study was designed to assess patient adherence to wearable cardioverter defibrillator as an indi...